BDPT BIOADAPTIVES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%
Returns
ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4,993 | $4,988 | $5,514 | $10,427 | $4,632 | $3,219 | $0 | $0 |
| Cost of revenue | $979 | $748 | $1,401 | $2,844 | $781 | $2,156 | $0 | $0 |
| Gross profit | $4,014 | $4,240 | $4,113 | $7,583 | $3,851 | $1,063 | $0 | $0 |
| SG&A expense | $235,592 | $177,745 | $181,050 | $228,262 | $250,971 | $197,892 | $143,383 | $258,621 |
| Operating income | -$292,498 | -$197,176 | -$198,218 | -$248,117 | -$265,689 | -$279,219 | -$249,148 | -$337,339 |
| Interest expense | $146,940 | $115,038 | $87,757 | $37,431 | $14,153 | $9,649 | $9,647 | $9,697 |
| Pretax income | -$1.50M | $150,090 | -$111,086 | -$823,346 | -$379,502 | -$157,914 | -$197,136 | -$371,788 |
| Net income | -$1.50M | $150,090 | -$111,086 | -$823,346 | -$379,502 | -$157,914 | -$197,136 | -$371,788 |
| EBITDA | -$290,998 | -$195,676 | -$196,718 | -$246,617 | -$264,189 | -$278,219 | -$249,148 | -$337,339 |
| EPS (basic) | -0.01 | 0.01 | — | — | -0.04 | -0.02 | — | — |
| EPS (diluted) | — | 0.00 | -0.01 | — | -0.04 | -0.02 | -0.02 | — |
| Weighted avg. shares (diluted) | — | 281.20M | 12.01M | — | 10.24M | 9.53M | 9.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5,144 | $29,221 | $73,606 | $158,445 | $59,273 | $210,582 | $39,564 | $137,470 |
| Short-term investments | — | $0 | $0 | $0 | — | — | — | $0 |
| Inventory | $34,197 | $36,046 | $42,968 | $44,706 | $44,228 | $39,574 | $40,584 | $19,115 |
| Current assets | $48,006 | $67,767 | $123,449 | $211,901 | $108,860 | $255,515 | $110,448 | $261,885 |
| PP&E, net | $9,500 | $11,000 | $12,500 | $14,000 | $15,500 | $17,000 | — | $0 |
| Intangibles | — | — | — | $14,000 | — | — | — | $0 |
| Total assets | $57,506 | $78,767 | $135,949 | $225,901 | $124,360 | $272,515 | $110,448 | $261,885 |
| Current liabilities | $2.70M | $1.84M | $2.27M | $2.36M | $1.59M | $1.41M | $1.68M | $1.73M |
| Total liabilities | $2.70M | $1.84M | $2.27M | $2.36M | $1.59M | $1.41M | $1.68M | $1.73M |
| Shareholders' equity | -$2.65M | -$1.77M | -$2.14M | -$2.13M | -$1.47M | -$1.23M | -$1.57M | -$1.46M |
| Shares outstanding | 223.68M | 36.60M | 12.01M | 12.01M | 10.94M | 9.95M | 9.05M | 8.22M |
| Cash flow statement | ||||||||
| Operating cash flow | -$113,531 | -$44,385 | -$84,839 | -$155,828 | -$151,309 | -$110,982 | -$97,906 | -$100,538 |
| Capital expenditure | $0 | — | — | $0 | $0 | — | — | $0 |
| Free cash flow | -$113,531 | — | — | -$155,828 | -$151,309 | — | — | -$100,538 |
| Investing cash flow | $0 | — | — | $0 | $0 | — | — | $0 |
| Financing cash flow | $89,454 | — | — | $255,000 | $0 | — | — | $194,115 |
| Depreciation & amortization | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | $1,000 | $0 | $0 |
| Stock-based compensation | $388,500 | — | — | -$310,000 | $105,000 | $28,670 | — | — |
Free plan shows the latest 8 periods; Pro shows all 48 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.